$343 Million is the total value of CHI Advisors LLC's 19 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was 14.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| RXDX | Buy | PROMETHEUS BIOSCIENCES INC | $67,859,000 | -3.1% | 2,862,059 | +0.4% | 19.81% | +21.6% |
| CGEM | Buy | CULLINAN ONCOLOGY INC | $50,666,000 | -12.3% | 2,244,841 | +0.1% | 14.79% | +10.1% |
| PLRX | Buy | PLIANT THERAPEUTICS INC | $41,942,000 | -39.2% | 2,484,724 | +4.9% | 12.24% | -23.7% |
| VECT | Buy | VECTIVBIO HLDG AG | $20,028,000 | -33.6% | 2,592,602 | +0.3% | 5.85% | -16.7% |
| New | OMEGA THERAPEUTICS INC | $19,904,000 | – | 1,055,882 | +100.0% | 5.81% | – | |
| ONCR | Buy | ONCORUS INC | $16,401,000 | -31.5% | 1,755,979 | +1.2% | 4.79% | -14.1% |
| FRLN | Buy | FREELINE THERAPEUTICS HLDGSsponsored ads | $4,867,000 | -56.7% | 1,427,481 | +3.5% | 1.42% | -45.7% |
| OVID | Buy | OVID THERAPEUTICS INC | $785,000 | -8.1% | 233,510 | +6.9% | 0.23% | +15.1% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-11-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| PRECISION BIOSCIENCES INC | 17 | Q3 2023 | 13.4% |
| OVID THERAPEUTICS INC | 17 | Q3 2023 | 5.8% |
| CORVUS PHARMACEUTICALS INC | 16 | Q2 2023 | 1.8% |
| KEZAR LIFE SCIENCES INC | 15 | Q1 2023 | 5.8% |
| PLIANT THERAPEUTICS INC | 14 | Q3 2023 | 29.2% |
| REPARE THERAPEUTICS INC | 14 | Q3 2023 | 30.3% |
| ORCHARD THERAPEUTICS PLC | 14 | Q4 2022 | 52.6% |
| LARIMAR THERAPEUTICS INC | 14 | Q3 2023 | 9.1% |
| KEROS THERAPEUTICS INC | 14 | Q3 2023 | 8.6% |
| INOZYME PHARMA INC | 13 | Q3 2023 | 9.4% |
View CHI Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Corvus Pharmaceuticals, Inc. | February 13, 2023 | 2,384,402 | 5.1% |
| Cullinan Oncology, Inc. | February 13, 2023 | 3,317,544 | 7.2% |
| Freeline Therapeutics Holdings plc | February 13, 2023 | 4,814,419 | 7.4% |
| Inozyme Pharma, Inc. | February 13, 2023 | 2,204,876 | 5.5% |
| Larimar Therapeutics, Inc. | February 13, 2023 | 3,473,366 | 8.0% |
| Oncorus, Inc. | February 13, 2023 | 2,367,436 | 9.1% |
| Orchard Therapeutics plc | February 13, 2023 | 7,987,396 | 6.3% |
| PLIANT THERAPEUTICS, INC. | February 13, 2023 | 3,199,892 | 6.6% |
| Repare Therapeutics Inc. | February 13, 2023 | 2,800,126 | 6.7% |
| VectivBio Holding AG | February 13, 2023 | 5,492,893 | 8.8% |
View CHI Advisors LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-11-13 |
| 13F-HR/A | 2023-08-22 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-11 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
View CHI Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.